STOCK TITAN

[SCHEDULE 13G/A] Compass Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Amendment to Schedule 13G correcting an earlier administrative error. RTW Investments, LP and Roderick Wong state that, as of June 30, 2025, they did not beneficially own any ordinary shares of Compass Therapeutics, Inc.; the filing reports 0 shares and 0.0% ownership. RTW Investments is identified as an investment adviser to certain funds and Dr. Wong is identified as Managing Partner and Chief Investment Officer. The amendment clarifies that an earlier Schedule 13G related to this issuer was filed inadvertently and this filing corrects that error.

Emendamento al Schedule 13G per correggere un precedente errore amministrativo. RTW Investments, LP e Roderick Wong dichiarano che, al 30 giugno 2025, non detenevano in via beneficiaria azioni ordinarie di Compass Therapeutics, Inc.; il modulo riporta 0 azioni e una partecipazione del 0,0%. RTW Investments è indicata come advisor di investimento per alcuni fondi e il dott. Wong è indicato come Managing Partner e Chief Investment Officer. L'emendamento chiarisce che un precedente Schedule 13G relativo a questo emittente era stato presentato involontariamente e che questa comunicazione corregge tale errore.

Enmienda al Schedule 13G para corregir un error administrativo anterior. RTW Investments, LP y Roderick Wong declaran que, a 30 de junio de 2025, no poseían en forma beneficiaria acciones ordinarias de Compass Therapeutics, Inc.; la presentación informa de 0 acciones y una participación del 0,0%. RTW Investments se identifica como asesor de inversión de determinados fondos y el Dr. Wong figura como Managing Partner y Chief Investment Officer. La enmienda aclara que un Schedule 13G anterior relacionado con este emisor se presentó por error y que esta presentación corrige dicho error.

이전의 행정적 오류를 정정하기 위한 Schedule 13G 수정서. RTW Investments, LP와 Roderick Wong은 2025년 6월 30일 현재 Compass Therapeutics, Inc.의 보통주를 실질적으로 보유하고 있지 않다고 밝힙니다; 제출 서류는 0주0.0% 보유로 보고합니다. RTW Investments는 일부 펀드의 투자 자문사로 명시되어 있으며 Wong 박사는 매니징 파트너 겸 최고투자책임자(Chief Investment Officer)로 명시됩니다. 이번 수정서는 해당 발행인에 관해 이전에 제출된 Schedule 13G가 실수로 제출되었음을 명확히 하며, 이 제출이 그 오류를 정정합니다.

Amendement au Schedule 13G corrigeant une erreur administrative antérieure. RTW Investments, LP et Roderick Wong déclarent que, au 30 juin 2025, ils ne détenaient aucune action ordinaire de Compass Therapeutics, Inc. à titre bénéficiaire ; le dépôt indique 0 actions et une participation de 0,0%. RTW Investments est identifié comme conseiller en investissement pour certains fonds et le Dr Wong est indiqué comme Managing Partner et Chief Investment Officer. L'amendement précise qu'un Schedule 13G antérieur relatif à cet émetteur a été déposé par inadvertance et que ce dépôt corrige cette erreur.

Nachtrag zum Schedule 13G zur Korrektur eines früheren administrativen Fehlers. RTW Investments, LP und Roderick Wong geben an, dass sie zum 30. Juni 2025 keine wirtschaftlich beherrschenden Stammaktien von Compass Therapeutics, Inc. besaßen; die Meldung weist 0 Aktien und einen Anteil von 0,0% aus. RTW Investments wird als Anlageberater für bestimmte Fonds geführt und Dr. Wong wird als Managing Partner und Chief Investment Officer genannt. Der Nachtrag stellt klar, dass ein zuvor eingereichter Schedule 13G zu diesem Emittenten irrtümlich eingereicht wurde und diese Meldung den Fehler berichtigt.

Positive
  • Correction filed to address an inadvertent prior Schedule 13G, improving transparency
  • Clear statement that Reporting Persons hold 0 shares (0.0%), removing ambiguity about ownership
Negative
  • An earlier Schedule 13G was inadvertently filed, creating a need for this corrective amendment

Insights

TL;DR: Amendment confirms no position; administrative correction reduces ambiguity about reported ownership.

The amendment clarifies that the Reporting Persons—RTW Investments, LP and Roderick Wong—hold 0 shares (0.0%) of Compass Therapeutics, Inc. as of June 30, 2025. From a market-impact perspective, this is a corrective, non-economic disclosure: it removes potential confusion created by the earlier inadvertent filing. There is no change to ownership that would affect control, voting outcomes, or trigger statutory thresholds.

TL;DR: Filing is procedural; it documents remediation of an inadvertent filing and confirms no beneficial ownership.

The Schedule 13G/A serves to correct an administrative error and formally record that the Reporting Persons possess no voting or dispositive power over the issuer's shares. This reduces regulatory ambiguity and demonstrates adherence to reporting obligations, but it does not present material corporate-governance or control implications because reported ownership remains at 0.0%.

Emendamento al Schedule 13G per correggere un precedente errore amministrativo. RTW Investments, LP e Roderick Wong dichiarano che, al 30 giugno 2025, non detenevano in via beneficiaria azioni ordinarie di Compass Therapeutics, Inc.; il modulo riporta 0 azioni e una partecipazione del 0,0%. RTW Investments è indicata come advisor di investimento per alcuni fondi e il dott. Wong è indicato come Managing Partner e Chief Investment Officer. L'emendamento chiarisce che un precedente Schedule 13G relativo a questo emittente era stato presentato involontariamente e che questa comunicazione corregge tale errore.

Enmienda al Schedule 13G para corregir un error administrativo anterior. RTW Investments, LP y Roderick Wong declaran que, a 30 de junio de 2025, no poseían en forma beneficiaria acciones ordinarias de Compass Therapeutics, Inc.; la presentación informa de 0 acciones y una participación del 0,0%. RTW Investments se identifica como asesor de inversión de determinados fondos y el Dr. Wong figura como Managing Partner y Chief Investment Officer. La enmienda aclara que un Schedule 13G anterior relacionado con este emisor se presentó por error y que esta presentación corrige dicho error.

이전의 행정적 오류를 정정하기 위한 Schedule 13G 수정서. RTW Investments, LP와 Roderick Wong은 2025년 6월 30일 현재 Compass Therapeutics, Inc.의 보통주를 실질적으로 보유하고 있지 않다고 밝힙니다; 제출 서류는 0주0.0% 보유로 보고합니다. RTW Investments는 일부 펀드의 투자 자문사로 명시되어 있으며 Wong 박사는 매니징 파트너 겸 최고투자책임자(Chief Investment Officer)로 명시됩니다. 이번 수정서는 해당 발행인에 관해 이전에 제출된 Schedule 13G가 실수로 제출되었음을 명확히 하며, 이 제출이 그 오류를 정정합니다.

Amendement au Schedule 13G corrigeant une erreur administrative antérieure. RTW Investments, LP et Roderick Wong déclarent que, au 30 juin 2025, ils ne détenaient aucune action ordinaire de Compass Therapeutics, Inc. à titre bénéficiaire ; le dépôt indique 0 actions et une participation de 0,0%. RTW Investments est identifié comme conseiller en investissement pour certains fonds et le Dr Wong est indiqué comme Managing Partner et Chief Investment Officer. L'amendement précise qu'un Schedule 13G antérieur relatif à cet émetteur a été déposé par inadvertance et que ce dépôt corrige cette erreur.

Nachtrag zum Schedule 13G zur Korrektur eines früheren administrativen Fehlers. RTW Investments, LP und Roderick Wong geben an, dass sie zum 30. Juni 2025 keine wirtschaftlich beherrschenden Stammaktien von Compass Therapeutics, Inc. besaßen; die Meldung weist 0 Aktien und einen Anteil von 0,0% aus. RTW Investments wird als Anlageberater für bestimmte Fonds geführt und Dr. Wong wird als Managing Partner und Chief Investment Officer genannt. Der Nachtrag stellt klar, dass ein zuvor eingereichter Schedule 13G zu diesem Emittenten irrtümlich eingereicht wurde und diese Meldung den Fehler berichtigt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Explanatory Note: This Amendment No. 1 to Schedule 13G (this "Amendment") is being filed to correct an administrative error in connection with the filing earlier today of a Schedule 13G by RTW Investments, LP and Roderick Wong (the "Reporting Persons"), which was inadvertently filed with the Securities and Exchange Commission with respect to Compass Therapeutics, Inc. As of June 30, 2025 the Reporting Persons did not own any shares of Compass Therapeutics, Inc. and this amendment is being filed to correct this administrative error.


SCHEDULE 13G




Comment for Type of Reporting Person: Explanatory Note: This Amendment No. 1 to Schedule 13G (this "Amendment") is being filed to correct an administrative error in connection with the filing earlier today of a Schedule 13G by RTW Investments, LP and Roderick Wong (the "Reporting Persons"), which was inadvertently filed with the Securities and Exchange Commission with respect to Compass Therapeutics, Inc. As of June 30, 2025 the Reporting Persons did not own any shares of Compass Therapeutics, Inc. and this amendment is being filed to correct this administrative error.


SCHEDULE 13G



RTW Investments, LP
Signature:/s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D., Managing Partner
Date:08/14/2025
Roderick Wong
Signature:s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D.
Date:08/14/2025

FAQ

What does the Schedule 13G/A filed by RTW Investments say about CMPX ownership?

The amendment states that RTW Investments, LP and Roderick Wong beneficially own 0 shares of Compass Therapeutics, Inc., representing 0.0% of the class as of June 30, 2025.

Why was this amendment filed for Compass Therapeutics (CMPX)?

The amendment was filed to correct an administrative error from an earlier Schedule 13G that was inadvertently submitted.

Who are the Reporting Persons in this filing?

The Reporting Persons are RTW Investments, LP (an investment adviser) and Roderick Wong, M.D. (Managing Partner and Chief Investment Officer).

Does the filing indicate any voting or dispositive power over CMPX shares?

No. The filing reports 0 sole and 0 shared voting power and 0 sole and 0 shared dispositive power for each Reporting Person.

Is there any indication the Reporting Persons own more than 5% of CMPX?

No. The filing specifies ownership of 0.0%, which is well below the 5% threshold.
Compass Therapeutics Inc

NASDAQ:CMPX

CMPX Rankings

CMPX Latest News

CMPX Latest SEC Filings

CMPX Stock Data

428.68M
101.95M
14.16%
67.97%
5.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON